Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2743.

https://doi.org/10.1182/blood-2018-99-116391

Published: 2018

Journal Articles

Predictive Response Biomarkers for BET Inhibitors in AML

Joseph J Saad, MSc, BSc, Juho Miettinen, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Samuli Eldfors, PhD, Mika Kontro, MD, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Jing Tang, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2018-99-118363

Published: 2018

Journal Articles

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Brian S. White, PhD, Suleiman A. Khan, PhD, Muhammad Ammad-ud-din, PhD, Swapnil Potdar, MSc, Mike J Mason, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD, Caroline A Heckman, PhD, Olli Kallioniemi, MD PhD, Stephen E Kurtz, PhD, Kimmo Porkka, MD PhD, Jeffrey W. Tyner, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Justin Guinney, PhD

Blood (2018) 132 (Supplement 1): 2763.

https://doi.org/10.1182/blood-2018-99-111916

Published: 2018

Journal Articles

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Shady Awad, MD, Matti Kankainen, PhD, Olli Dufva, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2018-99-111602

Published: 2018

Journal Articles

Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9

Riikka Karjalainen, Minxia Liu, Ashwini Kumar, MRes, Alun Parsons, Liye He, Dishaben Rameshbhai Malani, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2634.

https://doi.org/10.1182/blood-2018-99-118890

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Oscar Brück, MD, Olli Dufva, Sami Blom, MSc, Riku Turkki, MSc, Mette Ilander, PhD, Sanna M. Siitonen, MD PhD, Panu Kovanen, MD PhD, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Hanna Lähteenmäki, Katja Välimäki, Antonio Ribeiro, BSc, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2018-99-116628

Published: 2018

Journal Articles

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

Mahesh Tambe, PhD, Ella Karjalainen, MSc, Markus Vaha-Koskela, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2210.

https://doi.org/10.1182/blood-2018-99-118289

Published: 2018

Journal Articles

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Ashwini Kumar, MRes, Dishaben Rameshbhai Malani, MSc, Bhagwan Yadav, PhD, Matti Kankainen, PhD, Swapnil Potdar, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Simon Anders, PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 1398.

https://doi.org/10.1182/blood.V130.Suppl_1.1398.1398

Published: 2017

Journal Articles

Aspariginase-Triggered Hyperglycerimedia: An Analysis on Germline Regulatory Gene Variations in Adult Acute Lymphoblastic Leukemia Patients

Sari Kytölä, MD, Suvi Rantamo, MSc, Matti Jauhiainen, PhD, Kimmo Porkka, MD PhD, Outi Kilpivaara, PhD, Ulla Wartiovaara-Kautto, MD PhD

Blood (2017) 130 (Supplement 1): 1287.

https://doi.org/10.1182/blood.V130.Suppl_1.1287.1287

Published: 2017

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

High Amount of PD1+TIM3+ T Helper Cells May Predict Poor Outcome in Adult Acute Lymphoblastic Leukemia

Helena Hohtari, MD, Oscar Brück, Sami Blom, MSc, Riku Turkki, MSc, Antonio Ribeiro, BSc, Marjatta Sinisalo, MD PhD, Panu Kovanen, MD PhD, Olli Kallioniemi, MD PhD, Teijo Pellinen, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 3985.

https://doi.org/10.1182/blood.V130.Suppl_1.3985.3985

Published: 2017

Journal Articles

Extensive Immunosuppression in the Acute Myeloid Leukemia (AML) Bone Marrow and Discovery of NK Cells As Biomarker of Superior Survival

Oscar Brück, Sami Blom, MSc, Olli Dufva, BSc, Riku Turkki, MSc, Antonio Ribeiro, BSc, Sanna Siitonen, MD PhD, Panu Kovanen, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2017) 130 (Supplement 1): 3943.

https://doi.org/10.1182/blood.V130.Suppl_1.3943.3943

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Muntasir M Majumder, MSc, BPharm, David Tamborero, PhD, Pekka Anttila, Raija Helena Silvennoinen, MD, Samuli Eldfors, MSc, Juha Lievonen, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Esa Jantunen, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 4412.

https://doi.org/10.1182/blood.V130.Suppl_1.4412.4412

Published: 2017

Journal Articles

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, Bhagwan Yadav, PhD, Soili Kytölä, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 250.

https://doi.org/10.1182/blood.V130.Suppl_1.250.250

Published: 2017

Journal Articles

Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax

Riikka Karjalainen, Minxia Liu, Ashwini Kumar, MRes, Alun Parsons, Mika Kontro, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 298.

https://doi.org/10.1182/blood.V130.Suppl_1.298.298

Published: 2017

Journal Articles

CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism

Paavo Pietarinen, MSc, Perttu Koskenvesa, MD, Judith Klievink, Kimmo Porkka, MD PhD, Mikko Niemi, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 3071.

https://doi.org/10.1182/blood.V128.22.3071.3071

Published: 2016

Journal Articles

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Jarno Kivioja, MSc, Angeliki Thanasopoulou, PhD, Mika Kontro, MD, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Juerg Schwaller, MD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 4711.

https://doi.org/10.1182/blood.V128.22.4711.4711

Published: 2016

NARROW

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Predictive Response Biomarkers for BET Inhibitors in AML

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Aspariginase-Triggered Hyperglycerimedia: An Analysis on Germline Regulatory Gene Variations in Adult Acute Lymphoblastic Leukemia Patients

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

High Amount of PD1+TIM3+ T Helper Cells May Predict Poor Outcome in Adult Acute Lymphoblastic Leukemia

Extensive Immunosuppression in the Acute Myeloid Leukemia (AML) Bone Marrow and Discovery of NK Cells As Biomarker of Superior Survival

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax

CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only